Targeting cancer with antibody-drug conjugates: Promises and challenges.

mAbs5.30
Volume: 13, Issue: 1, Pages: 1951427 - 1951427
Published: Jan 1, 2021
Abstract
Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved ten ADCs, namely Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Polivy®, Padcev®, Enhertu®, Trodelvy®, Blenrep®, and Zynlonta™ as monotherapy or combinational therapy for breast cancer, urothelial cancer, myeloma,...
Paper Details
Title
Targeting cancer with antibody-drug conjugates: Promises and challenges.
Published Date
Jan 1, 2021
Journal
Volume
13
Issue
1
Pages
1951427 - 1951427
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.